Key features and details
- Rat monoclonal [6D5] to CD19 (PE/Cy5.5®)
- Suitable for: Flow Cyt, IP, Functional Studies
- Reacts with: Mouse
- Conjugation: PE/Cy5.5®. Ex: 496nm, Em: 690nm
- Isotype: IgG2a
Product nameAnti-CD19 antibody [6D5] (PE/Cy5.5®)
See all CD19 primary antibodies
DescriptionRat monoclonal [6D5] to CD19 (PE/Cy5.5®)
ConjugationPE/Cy5.5®. Ex: 496nm, Em: 690nm
SpecificityCD19 B-cell differentiation antigen
Tested applicationsSuitable for: Flow Cyt, IP, Functional Studiesmore details
Species reactivityReacts with: Mouse
Mouse CD19-expressing K562 human erythroleukemia cells
General notesThis product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: PBS, 16% Sucrose
Also contains a stabilizing agent.
Concentration information loading...
Light chain typekappa
Our Abpromise guarantee covers the use of ab25548 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at an assay dependent dilution.
In vivo and in vitro functional studies:Use at an assay dependent dilution.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
modificationsPhosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
- Information by UniProt
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
ab25548 has been referenced in 3 publications.
- Krop I et al. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol 26:238-42 (1996). PubMed: 8566073
- Krop I et al. The signaling activity of murine CD19 is regulated during cell development. J Immunol 157:48-56 (1996). PubMed: 8683154
- Fearon DT The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Curr Opin Immunol 5:341-8 (1993). PubMed: 7688513